ALB and cytomegalovirus infection: Age (49 y ±9.1 y vs. 52.7 y ±8.7 y), male sex (52.4% vs. 41.2%), HCV infection (22.5% vs. 18.8%), HBV infection (9.8% vs. 17.6%), CMV infection (17.5% vs. 18.8%), creatinine change (0.005 [−0.05, 0.142] mg/dL vs. 0.015 [−0.082, 0.162] mg/dL), serum albumin change (−0.06 [−0.225, 0.075] g/L vs. −0.02 [−0.215, 0.15] g/L), hip bone BMD change (−0.0005 [−0.021, 0.019] g/cm2 vs. 0.018 [−0.011, 0.034] g/cm2), and femoral neck BMD change (0 [−0.022, 0.021] g/cm2 vs. 0.005 [−0.022, 0.021] g/cm2) were not significantly different (p>0.05) between alendronate and non-alendronate patients.